Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies

CONCLUSION: In this study, belimumab reduced the anti-phospholipid antibodies while increasing the platelet count in SLE patients with anti-phospholipid antibody-associated immune thrombocytopenia.PMID:37650252 | DOI:10.1080/03009742.2023.2247881

Source: Scandinavian Journal of Rheumatology - August 31, 2023 Category: Rheumatology Authors: J Dong L Zhao L Pan H Wang L Wang Source Type: research